Predictive Potential of ECMO Blood Flow for Hemolysis and Outcome of Patients with Severe ARDS.

Treatment with veno-venous extracorporeal membrane oxygenation (VV ECMO) has become a frequently considered rescue therapy in patients with severe acute respiratory distress syndrome (ARDS). Hemolysis is a common complication in patients treated with ECMO. Currently, it is unclear whether increased ECMO blood flow (Q̇) contributes to mortality and might be associated with increased hemolysis. A total of 441 patients with ARDS and VV ECMO, treated in a tertiary ARDS center, were included. The Q̇ value for a significant increase in ICU mortality was determined by binary recursive partitioning. Linear regression analysis was performed to analyze a correlation between mean Q̇ and mean plasma concentrations of cell-free hemoglobin (CFH). A Q̇ of 4 L/min divided the cohort into two groups with significantly different ICU mortality (Q̇ ≤ 4 L/min: 39.3% ( = 300) versus Q̇ > 4 L/min: 71.6% ( = 141), < 0.001). Patients with Q̇ > 4 L/min had a higher 28-day mortality. Furthermore, a higher mean Q̇ was associated with increased CFH and decreased haptoglobin plasma concentrations. In patients with ARDS and VV ECMO, a mean Q̇ > 4 L/min is associated with increased mortality, increased CFH and decreased haptoglobin plasma concentrations. Whether increased hemolysis determines the poorer outcome associated with higher Q̇ should be the subject of future research.